A drug use evaluation was conducted to determine if reteplase was administered expeditiously, appropriately, and safely to patients arriving in the emergency department (ED) with acute myocardial infaction (AMI). A retrospective review of the medical records of 28 patients receiving reteplase in the ED during a 6-month period was conducted. The median door-to-drug time for administration of reteplase was 33 minutes. Major and minor bleeding events occurred in 3.6% and 42.8% of patients, respectively. In general, reteplase was administered correctly and in a timely manner to appropriately screened patients.
Heart and Stroke Facts: 1996 Statistical Supplement.Dallas, TX: American Heart Association; 1995.
2.
RyanT.J., AndersonJ.L., AntmanE.M.ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).J Am Coll Cardiol.1996; 28: 1328–428.
3.
GISSI-1.Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.Lancet.1986; 1: 397–402.
4.
Gusto Investigators.An international randomized trial comprising four thrombolytic strategies for acute myocardial infarction (GUSTO).N Eng J Med.1993; 329: 673–82.
5.
Gusto III Investigators.A comparison of reteplase with alteplase for acute myocardial infarction.N Eng J Med.1997; 337: 1118–23.
6.
OhmanE.M., HarringtonR.A.Intravenous thrombolysis in acute myocardial infarction.Chest.2001; 119: 253s–77s.
GoldbergR.J., MooraddM.Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infaction (The Second National Registry of Myocardial Infarction).Am J Card.1998; 82: 259–64
9.
LATE investigators.Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6–24 hours after onset of AMI.Lancet.1993; 342: 759–66.
10.
SarginM.J., CannonC.P., CermignaniM.S.Delay in thrombolysis administration: Causes of extended door-to-drug times and the asymptote effect.J Emerg Med.1998, 16(4); 557–65.
11.
CannonC.P., JohnsonE.B., CermignaniM.Emergency department thrombolysis critical pathway reduces door-to-drug times in acute myocardial infarction.Clin Cardiol.1999; 22: 17–20.
12.
CagenE.L., FeinbergR., StaryM.Tissue plasminogen activator use evaluation.Pharm Therapeutics.1996; 387–96.
13.
Inject Investigators.Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence.Lancet.1995; 346: 329–36.
14.
SmallingR.W., BodeC., KalbfleischJ.More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction.Circulation.1995; 91: 2725–32.
15.
RyanT.J., AntmanE.M., BrooksN.H.1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol.1999; 34(3): 890–911.
